Discover 363 paid clinical trials in Quebec City, Quebec. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 363
Active & Responsive
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
for
Nonsegmental Vitiligo
Location: Quebec, Fredericton, Peterborough, New York NY, Barrie,
Sponsor: Takeda
Sex: All
Age: 18 - 70+
Code: NCT07108283
Phase2, Recruiting
Active & Responsive
Study of EVO756 in Adults With Migraine
for
Migraine
Location: Quebec, Foxborough MA, Westborough MA, New Haven CT,
Sponsor: Evommune, Inc.
Sex: All
Age: 18 - 64
Code: NCT07616128
Phase2, Recruiting
Active & Responsive
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
for
Atopic Dermatitis
Location: Quebec, Chicoutimi, Johnston RI, East Syracuse NY,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT05995964
Phase2, Recruiting
Active & Responsive
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
for
Menstrual Migraine
Location: Levis, East Greenwich RI, Halifax, Rochester NY,
Sponsor: Pfizer
Sex: Female
Age: 18 - 45
Code: NCT06641466
Phase3, Recruiting
Active & Responsive
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
for
Prostatic Neoplasms, Castration-Resistant
Location: Quebec, Montreal, Ottawa, Boston MA, The Bronx NY,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07225946
Phase3, Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
for
Metastatic Digestive System Neuroendocrine Tumor G1,